Guidelines: Finnish Medical Association Duodecim Guidelines (Finland): Difference between revisions
From Beacon
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{forproviders}} | {{forproviders}} {{forpolicymakers}} | ||
Go back to [[Finland]] page | Go back to [[Finland]] page | ||
''' | '''Primary purpose:''' To provide independent national treatment recommendations based on research evidence. | ||
''' | '''Sponsor, manager or home institution:''' [[dataOwner::Duodecim of the Finnish Medical Society]] and other institutions. | ||
'''Type of information:''' Treatment recommendations; Epidemiology and etiology; Prevalence classification and histological classification; Diagnostics; Monitoring; Quality of life of patients of prostate, lung, oral cancer and palliative care and hospice care recommendations. [https://www.kaypahoito.fi/suositukset?erikoisala=2436 Click here to learn more]. | |||
''' | '''Cancer areas of interest:''' [[hasCancerType::C00-C97: All cancer types]]. [https://www.kaypahoito.fi/suositukset?erikoisala=2436 Click here to learn more]. | ||
'''Access to information:''' | '''Access to information:''' [https://www.kaypahoito.fi/suositukset?erikoisala=2436 Click here to access]. | ||
Revision as of 19:04, 13 May 2024
Go back to Finland page
Primary purpose: To provide independent national treatment recommendations based on research evidence.
Sponsor, manager or home institution: Duodecim of the Finnish Medical Society and other institutions.
Type of information: Treatment recommendations; Epidemiology and etiology; Prevalence classification and histological classification; Diagnostics; Monitoring; Quality of life of patients of prostate, lung, oral cancer and palliative care and hospice care recommendations. Click here to learn more.
Cancer areas of interest: C00-C97: All cancer types. Click here to learn more.
Access to information: Click here to access.
